Clinical Data and Other Research Results Regarding VASCEPA® (Icosapent Ethyl) and Its Unique Active Ingredient to Be Presented at the American College of Cardiology’s 70th Annual Scientific Session Read more about Clinical Data and Other Research Results Regarding VASCEPA® (Icosapent Ethyl) and Its Unique Active Ingredient to Be Presented at the American College of Cardiology’s 70th Annual Scientific Session
Amarin Reports First Quarter 2021 Financial Results and Provides Business Update Read more about Amarin Reports First Quarter 2021 Financial Results and Provides Business Update
Amarin Announces Planned Retirement of Joseph T. Kennedy, EVP, General Counsel Read more about Amarin Announces Planned Retirement of Joseph T. Kennedy, EVP, General Counsel
Amarin Receives Great Britain Marketing Authorization for VAZKEPA from the Medicines and Healthcare Products Regulatory Agency (MHRA) 1,2 Read more about Amarin Receives Great Britain Marketing Authorization for VAZKEPA from the Medicines and Healthcare Products Regulatory Agency (MHRA) 1,2
Amarin to Report First Quarter Results and Host Conference Call on April 29, 2021 Read more about Amarin to Report First Quarter Results and Host Conference Call on April 29, 2021
VASCEPA® (Icosapent Ethyl) Reported to Impact Vulnerable Coronary Plaque Features in New Analyses of EVAPORATE Study Presented as Late-Breaking Science at ESC Preventive Cardiology 2021 Read more about VASCEPA® (Icosapent Ethyl) Reported to Impact Vulnerable Coronary Plaque Features in New Analyses of EVAPORATE Study Presented as Late-Breaking Science at ESC Preventive Cardiology 2021
Amarin Commences Commercial Initiatives for VAZKEPA in European Union Following Recent Regulatory Approval for Cardiovascular Risk Reduction Indication Read more about Amarin Commences Commercial Initiatives for VAZKEPA in European Union Following Recent Regulatory Approval for Cardiovascular Risk Reduction Indication
Amarin Receives European Commission (EC) Approval for VAZKEPA to Reduce Cardiovascular Risk Read more about Amarin Receives European Commission (EC) Approval for VAZKEPA to Reduce Cardiovascular Risk
Fifteen Medical Societies Now Recommend Icosapent Ethyl to Reduce Cardiovascular Risk, Further Supporting that VASCEPA® is Rapidly Becoming a New Standard of Care Read more about Fifteen Medical Societies Now Recommend Icosapent Ethyl to Reduce Cardiovascular Risk, Further Supporting that VASCEPA® is Rapidly Becoming a New Standard of Care